Product Description
oNKord is an Allogeneic ex vivo-generated Natural Killer (NK) cell candidate being developed by Glycostem Therapeutics for the treatment of acute myeloid leukemia. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04632316?term=oNKord&draw=2&rank=1)
Mechanisms of Action: NK Cells
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: Orphan Drug - Multiple Myeloma *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Glycostem Therapeutics
Company Location: Europe
Company Founding Year: 2007
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acute Myeloid Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05290662 |
ReKORD | N/A |
Recruiting |
Other |
2028-03-01 |
2022-08-05 |
Primary Endpoints|Start Date|Treatments |
|
NCT04632316 |
WiNK | P2 |
Unknown status |
Acute Myeloid Leukemia |
2023-04-01 |
20% |
2024-06-04 |
Primary Endpoints|Treatments|Trial Status |